Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in May Multiple strategies in place to enroll patients that are representative of ...

The U.S. Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every ...

Murky documentation of meetings between Biogen and the FDA, plus an “unjustifiably high price” for a drug that lacked clinical data, are at fault for the Adulelm controversy, two House committees said ...

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago. The company recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as said sales ...

Clinical trials studying Aduhelm only looked at a narrow group of patients. This month, the Food and Drug Administration approved a new treatment for Alzheimer’s disease-- the first in nearly 20 years ...

Stream NBC 5 for free, 24/7, wherever you are. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. It reported net income of $249.7 million, or $1.71 per ...

Biogen is discontinuing its Alzheimer’s drug Aduhelm, which was approved in 2021 but became snarled in efficacy concerns and payers’ refusals to cover the medication. The company said it sought ...